Metastatic hormone-sensitive and castration resistant prostate cancer.
Conditions
Interventions
None.
Sponsors
Radboud University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Patients who were treated in a participating hospital after 01-01-2016 and have: - metastatic HSPC, defined as involvement of lymph nodes, bones or viscera on radiological assessment or as defined by either the treating doctor/physician (i.e. palliative treatment with surgical or medical castration) - metastatic CRPC, defined by the treating doctor/physician or the definition of the European Urology Association (EAU)[10], as prostate cancer that is progressing despite medical or surgical castration (i.e. castrate levels of testosterone (= 50 ng/dL or <1.7 nmol/L)
Exclusion criteria
Exclusion criteria: None.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main objective is to assess effectiveness, efficiency and quality of treatments in HSPC and CRPC patients in the Netherlands. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To describe the population of HSPC and CRPC patients; - To assess treatment patterns and outcomes of systemic anti-cancer treatment in HSPC and CRPC; - Focus on systemic treatment (including hormonal therapy, chemotherapy, bone directed therapy, immunotherapy, targeted therapy), radiotherapy, radionuclides and surgery; - Focus on relevant and readily available outcomes (including overall survival, treatment duration, biochemical response, severe adverse events); - To assess guideline adherence of diagnostic evaluation and anti-cancer treatment; - To assess access of patients to treatment innovations, mainly clinical trials and new treatment options; - To evaluate differences in real-world populations and trial populations. | — |
Contacts
Public ContactDianne Bosch
Radboudumc
Outcome results
None listed